Low prevalence of IgA anti-transglutaminase 1, 2, and 3 autoantibodies in children with atopic dermatitis

BMC Research Notes

Raivo Uibo¹  Oivi Uibo²  Katrin Luts³  Kristi Lepik³  Urve Putnik³  Triine Annus³  Kaupo Teesalu¹  Krista Ress¹ 

[1] Department of Immunology, Institute of Bio- and Translational Medicine and Centre of Excellence for Translational Medicine, University of Tartu, Ravila 19, 50411 Tartu, Estonia;Children’s Clinic, Tartu University Hospital, Lunini 6, 51014 Tartu, Estonia;Tallinn Children’s Hospital, Tervise 28, 13419 Tallinn, Estonia

关键词: Transglutaminase 3;    Transglutaminase 2;    Transglutaminase 1;    Coeliac disease;    Atopic dermatitis;    Autoantibodies;   

Others  :  1132722
DOI  :  10.1186/1756-0500-7-310

 received in 2013-06-20, accepted in 2014-05-14,  发布年份 2014

【 摘 要 】

Background

Atopic dermatitis (AD) is a multifactorial chronic inflammatory skin disease presenting with a relapsing clinical pattern similar to chronic autoimmune disease. Several human transglutaminases have been defined and keratinocyte transglutaminase (TG1) and epidermal transglutaminase (TG3) expressed in the epidermis are associated with epidermal barrier dysfunction. Since impairments to the epidermal barrier represent an important factor in AD, we hypothesized that IgA autoantibodies specific for TG1 (IgA-anti-TG1) and TG3 (IgA-anti-TG3) may affect AD development during childhood.

Methods

Active AD patients (n = 304), 28 patients with biopsy-confirmed coeliac disease (CD), 5 patients with active AD and CD, and 55 control patients without CD and skin diseases were enrolled into the study. IgA-anti-TG1 and IgA-anti-TG3 reactivity was determined using an enzyme-linked immunosorbent assay. IgA-anti-TG2 were defined using a fluoroenzyme immunoassay.

Results

IgA-anti-TG1 antibodies were found in 2% and IgA-anti-TG3 antibodies in 3% of patients with active AD. Two out of the 5 patients with AD and concomitant CD had IgA-anti-TG1 and IgA-anti-TG2 antibodies. In CD patients, 36% of individuals presented with elevated IgA-anti-TG1 antibodies and 18% presented with elevated IgA-anti-TG3 antibodies and all CD patients presented with IgA-anti-TG2 antibodies (significantly different from AD patients and controls, p < 0.05). In CD patients, IgA-anti-TG1 and/or IgA-anti-TG3 seropositivity tended to appear concurrently, whereas only one patient with AD had both types of autoantibodies.

Conclusions

IgA-anti-TG1 and IgA-anti-TG3 seropositivity was rare in active AD but frequent in CD patients. The level of circulating antibodies related to skin lesions could be studied by determining the levels of IgA-anti-TG1 and IgA-anti-TG3 in skin biopsies of AD patients.

【 授权许可】

   
2014 Ress et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, Guy RH, MacGowan AL, Tazi-Ahnini R, Ward SJ: Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009, 129:1892-1908.
• [2]Tokura Y: Extrinsic and intrinsic types of atopic dermatitis. J Dermatol Sci 2010, 58:1-7.
• [3]Boguniewicz M, Leung DYM: Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev 2011, 242:233-246.
• [4]Novak N, Leung DYM: Advances in atopic dermatitis. Curr Opin Immunol 2011, 23:778-783.
• [5]Valenta R, Mittermann I, Werfel T, Garn H, Renz H: Linking allergy to autoimmune disease. Trends Immunol 2009, 30:109-116.
• [6]Tang TS, Bieber T, Williams HC: Does “autoreactivity” play a role in atopic dermatitis. J Allergy Clin Immunol 2012, 129:1209-1215.
• [7]Liedén A, Winge MCG, Sääf A, Kockum I, Ekelund E, Rodriquez E, Fölster-Holst R, Franke A, Illig T, Tengvall-Linder M, Baurecht H, Weidinger S, Wahlgren C-F, Nordenskjöld M, Bradley M: Genetic variation in the epidermal transglutaminase genes is not associated with atopic dermatitis. PLoS ONE 2012, 7:e49694.
• [8]Cheng T, Tjabringa GS, van Vlijmen-Willems IM, Hitomi K, van Erp PE, Schalkwijk J, Zeeuwen PL: The cystatin M/E-controlled pathway of skin barrier formation: expression of its key components in psoriasis and atopic dermatitis. Brit J Dermatol 2009, 161:253-264.
• [9]de Koning HD, van den Bogaard EH, Bergboer JGM, Kamsteeg M, van Clijmen-Willems IMJJ, Hitomi K, Henry J, Simon M, Takashita N, Ishida-Yamamoto A, Schalkwijk J, Zeeuwen PLJM: Expression profile of cornified envelope structural proteins and keratinocyte differentiation-regulating proteins during skin barrier repair. Brit J Dermatol 2012, 166:1245-1254.
• [10]Eckert RL, Sturniolo MT, Broome A-M, Ruse M, Rorke EA: Transglutaminase function in epidermis. J Invest Dermatol 2005, 124:481-492.
• [11]Park MK, Cho SA, Lee HJ, Lee EJ, Kang JH, Kim YL, Kim HJ, Oh SH, Choi C, Lee H, Kim SY, Lee CH: Suppression of Transglutaminase-2 is Involved in Anti-Inflammatory Actions of Glucosamine in 12-O-Tetradecanoylphorbol-13-Acetate-Induced Skin Inflammation. Biomol Ther 2012, 20:380-385.
• [12]Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, Schuppan D: Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997, 3:797-801.
• [13]Lagerqvist C, Dahlbom I, Hansson T, Jidell E, Juto P, Olcén P, Stenlund H, Hernell O, Ivarsson A: Antigliadin immunoglobulin A test in finding celiac disease in children younger than 18 months of age. J Pediatr Gastroenterol Nutr 2008, 47:428-435.
• [14]Husby S, Koletzko S, Korponay-Szabó IR, Mearin ML, Phillips A, Shamir R, Troncone R, Giersiepen K, Branski D, Catassi C, Lelgeman M, Mäki M, Ribes-Koninckx C, Ventura A, Zimmer KP, ESPGHAN Working Group on Coeliac Disease Diagnosis; ESPGHAN Gastroenterology Committee; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition: European Society for Pediatric Gastroenterology, Hepatology, and Nutrition Guidelines for the Diagnosis of Coeliac Disease. J Pediatr Gastroenterol Nutr 2012, 54:136-160.
• [15]Sárdy M, Kárpáti S, Merkl B, Paulsson M, Smyth N: Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med 2002, 195:747-757.
• [16]Hull CM, Liddle M, Hansen N, Meyer LJ, Schmidt L, Taylor T, Jaskowski TD, Hill HR, Zone JJ: Elevation of IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis. Brit J Dermatol 2008, 159:120-124.
• [17]Walker-Smith JA, Guandalini S, Schmitz J, Shmerling DH, Visakorpi JK: Revised criteria for diagnosis of coeliac disease. Report of Working Group of European Society of Paediatric Gastroenterology and Nutrition. Arch Dis Child 1990, 65:909-911.
• [18]Marsh MN: Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity (“celiac sprue”). Gastroenterology 1992, 102:330-354.
• [19]McGowan KE, Castiglione DA, Butzner JD: The changing face of childhood celiac disease in North America: impact of serological testing. Pediatrics 2009, 124:1572-1578.
• [20]Teesalu K, Agardh D, Panarina M, Utt M, Uibo O, Uibo R: A modified ELISA for improved detection of IgA, IgG, and IgM anti-tissue transglutaminase antibodies in celiac disease. Clin Chim Acta 2009, 403:37-41.
• [21]Marietta EV, Camilleri MJ, Castro LA, Krause PK, Pittelkow MR, Murray JA: Transglutaminase autoantibodies in dermatitis herpetiformis and celiac sprue. J Invest Dermatol 2008, 128:332-335.
• [22]Jaskowski TD, Hamblin T, Wilson A, Hill HR, Book LS, Meyer LJ, Zone JJ, Hull CM: IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis and pediatric celiac disease. J Invest Dermatol 2009, 129:2728-2730.
• [23]Bonciani D, Verdelli A, Bonciolini V, D’Errico A, Antiga E, Fabbri P, Caproni M: Dermatitis Herpetiformis: From the Genetics to the Development of Skin Lesions. Clin Dev Immunol 2012. doi:10.1155/2012/239691
• [24]Hadjivassiliou M, Aeshlimann P, Strigun A, Sanders DS, Woodrofe N, Aeschlimann D: Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase. Ann Neurol 2008, 64:332-343.